S&P 500
5,906.57
-0.3%
-$14.97
DJI
42,200.82
-0.3%
-$142.83
NASDAQ
19,176.65
-0.1%
-$22.51
Bitcoin
107,652.00
-1.7%
-1,823.29
AAPL
$201.04
+0.4%
+$0.83
AMZN
$205.53
-0.2%
-$0.49
GOOG
$174.36
+0.2%
+$0.38
META
$645.47
+0.5%
+$3.15
MSFT
$459.29
-0.3%
-$1.40
NVDA
$135.56
+0.0%
+$0.06
TSLA
$363.28
+0.1%
+$0.39
Jeff Fischer
TMFFischer
Jeff Fischer (TMFFischer) is advisor at Motley Fool Pro and co-advisor at Motley Fool Options.
Recent Articles by Jeff Fischer
Dec 21, 2016
by Jeff Fischer
Break Down: Human Genome Sciences
This year a small group of Fools visited the headquarters of a new paradigm drug company, Human Genome Sciences. Today that tour is summarized and the company is put through the first Rule Breaker criterion as we measure its top dog and first mover status in genomics-based biotech. With $8 billion in market value, there may be a great deal of long-term potential in HGS if it proves to be a Rule Breaker.
Dec 21, 2016
by Jeff Fischer
Campbell Soup On the Bubble
Campbell Soup has a few means to create value again, but the main one is to grow soup sales volume, which it has failed to do for three years. Other means (mergers, selling itself, new products) aren't likely to occur or be enough. The investment has changed enough that Drip Port is ready to replace it with something better. A new study will begin.
Dec 21, 2016
by Jeff Fischer
Break Down: Millennium Pharmaceuticals, Part 2
A Break Down analyzes a company's prospects based on our Rule Breaker criteria. We're spending the month Breaking Down several Rule Breaker candidates in search of a new purchase. Part two of our Break Down of Millennium Pharmaceuticals concludes that the company should be strongly considered.
Dec 21, 2016
by Jeff Fischer
Break Down: Millennium Pharmaceuticals
The Rule Breaker's study of potential investments continues with a Break Down of biopharmaceutical leader Millennium Pharmaceuticals. The company is the top dog of genomics-focused biotechs when measured by market value, size and number of partnerships, and drug pipeline.
Dec 21, 2016
by Jeff Fischer
Easing Into Pepsi
The Drip Port will begin to buy its additional shares of PepsiCo slowly and cautiously. This is partly due to lessons learned from Campbell Soup. With Campbell, the Drip Port rushed to buy shares at the start in order to balance the new position (based on dollars invested) with the port's older, much larger positions. Balancing of this nature may do more harm than good, however, as it did with Campbell Soup, because the
Dec 21, 2016
by Jeff Fischer
fool.com: The Rule Breaker Portfolio
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.